Trial · NCT03304379
Results by group64
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 64
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Scores up to Week 24 in Participants Treated With Fasinumab Compared to Placebo | Placebo | FAS | -2.21 | Standard Error 0.165 | Score on a Scale |
| Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Scores up to Week 24 in Participants Treated With Fasinumab Compared to Placebo | Fasinumab 1 mg | FAS | -2.84 | Standard Error 0.127 | Score on a Scale |
| Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Scores up to Week 24 in Participants Treated With Fasinumab Compared to Placebo | Placebo | mFAS | -2.01 | Standard Error 0.182 | Score on a Scale |
| Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Scores up to Week 24 in Participants Treated With Fasinumab Compared to Placebo | Fasinumab 1 mg | mFAS | -2.78 | Standard Error 0.141 | Score on a Scale |
| Change From Baseline in WOMAC Physical Function Subscale Scores up to Week 24 in Participants Treated With Fasinumab Compared to Placebo | Placebo | FAS | -2.02 | Standard Error 0.164 | Score on a Scale |
| Change From Baseline in WOMAC Physical Function Subscale Scores up to Week 24 in Participants Treated With Fasinumab Compared to Placebo | Fasinumab 1 mg | FAS | -2.65 | Standard Error 0.125 | Score on a Scale |
| Change From Baseline in WOMAC Physical Function Subscale Scores up to Week 24 in Participants Treated With Fasinumab Compared to Placebo | Placebo | mFAS | -1.80 | Standard Error 0.180 | Score on a Scale |
| Change From Baseline in WOMAC Physical Function Subscale Scores up to Week 24 in Participants Treated With Fasinumab Compared to Placebo | Fasinumab 1 mg | mFAS | -2.62 | Standard Error 0.138 | Score on a Scale |
Percentage of Participants With Greater Than or Equal to (≥) 30 Percent (%) Reduction From Baseline up to Week 24 in WOMAC Pain Subscale Score in Participants Treated With Fasinumab Compared to Placebo | Placebo | 48.7 | Percentage of Participants | ||
Percentage of Participants With Greater Than or Equal to (≥) 30 Percent (%) Reduction From Baseline up to Week 24 in WOMAC Pain Subscale Score in Participants Treated With Fasinumab Compared to Placebo | Fasinumab 1 mg | 59.8 | Percentage of Participants | ||
| Change From Baseline in Patient Global Assessment (PGA) Score up to Week 24 in Participants Treated With Fasinumab Compared to Placebo | Placebo | -0.66 | Standard Error 0.063 | Score on a Scale | |
| Change From Baseline in Patient Global Assessment (PGA) Score up to Week 24 in Participants Treated With Fasinumab Compared to Placebo | Fasinumab 1 mg | -0.81 | Standard Error 0.047 | Score on a Scale | |
| Change From Baseline in WOMAC Pain Subscale Scores up to Week 24 in Participants Treated With Fasinumab Compared to Participants Treated With NSAIDs | NSAIDs | FAS | -2.60 | Standard Error 0.128 | Score on a Scale |
| Change From Baseline in WOMAC Pain Subscale Scores up to Week 24 in Participants Treated With Fasinumab Compared to Participants Treated With NSAIDs | Fasinumab 1 mg | FAS | -2.84 | Standard Error 0.127 | Score on a Scale |
| Change From Baseline in WOMAC Pain Subscale Scores up to Week 24 in Participants Treated With Fasinumab Compared to Participants Treated With NSAIDs | NSAIDs | mFAS | -2.48 | Standard Error 0.140 | Score on a Scale |
| Change From Baseline in WOMAC Pain Subscale Scores up to Week 24 in Participants Treated With Fasinumab Compared to Participants Treated With NSAIDs | Fasinumab 1 mg | mFAS | -2.78 | Standard Error 0.141 | Score on a Scale |
| Change From Baseline in WOMAC Physical Function Subscale Scores up to Week 24 in Participants Treated With Fasinumab Compared to Participants Treated With NSAIDs | NSAIDs | FAS | -2.33 | Standard Error 0.127 | Score on a Scale |
| Change From Baseline in WOMAC Physical Function Subscale Scores up to Week 24 in Participants Treated With Fasinumab Compared to Participants Treated With NSAIDs | Fasinumab 1 mg | FAS | -2.65 | Standard Error 0.125 | Score on a Scale |
| Change From Baseline in WOMAC Physical Function Subscale Scores up to Week 24 in Participants Treated With Fasinumab Compared to Participants Treated With NSAIDs | NSAIDs | mFAS | -2.26 | Standard Error 0.140 | Score on a Scale |
| Change From Baseline in WOMAC Physical Function Subscale Scores up to Week 24 in Participants Treated With Fasinumab Compared to Participants Treated With NSAIDs | Fasinumab 1 mg | mFAS | -2.62 | Standard Error 0.138 | Score on a Scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03304379/results